The global fight against COVID-19 has taken a big step forward following a landmark deal between The University of Queensland (UQ) and pharma giant CSL.
Now, Australian scientists are planning to produce up to 100 million doses of a COVID-19 vaccine by the end of 2021 should clinical trials of the UQ vaccine prove successful.
The deal comes after promising early results in the laboratory. It will aim to fast-track the development of a home-grown vaccine.
UQ Vice-Chancellor Professor Peter Høj said progress had been encouraging.
“As global citizens in the race against this threat, we all recognise there is still much to be done and it will be a collective effort across borders until the risk is eradicated.”
The vaccine is distinct from other candidates under development because it uses what is known as a “molecular clamp” – a technology patented by the university.
Safety trials will start in Brisbane this month following the recruitment of participants for testing a COVID-19 vaccine.
In partnership with UQ and the Coalition for Epidemic Preparedness Innovations, CSL will develop, manufacture and distribute the potential vaccine.
Other potential COVID-19 vaccines are in the pipeline globally, with several already being trialled in humans.
Australian university research leads the way. Sign the petition to show your support for it and #KeepItClever today.